Article metrics
PDF
Other content recommended for you
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- Identifying priority medicines policy issues for New Zealand: a general inductive study
- Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry: a protocol paper
- International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study
- Advances in systemic therapy for non-small cell lung cancer
- Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
- Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
- Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice
- Novel cancer therapies: treatments driven by tumour biology
- Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)